We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PD‐L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance.
- Authors
Bhola, Neil E.; Njatcha, Christian; Hu, Lanlin; Lee, Eliot D.; Shiah, Jamie V.; Kim, Mi‐Ok; Johnson, Daniel E.; Grandis, Jennifer R.
- Abstract
Background: Tumor models resistant to EGFR tyrosine kinase inhibitors or cisplatin express higher levels of the immune checkpoint molecule PD‐L1. We sought to determine whether PD‐L1 expression is elevated in head and neck squamous cell carcinoma (HNSCC) models of acquired cetuximab resistance and whether the expression is regulated by bromodomain and extraterminal domain (BET) proteins. Methods: Expression of PD‐L1 was assessed in HNSCC cell line models of acquired cetuximab resistance. Proteolysis targeting chimera (PROTAC)‐ and RNAi‐mediated targeting were used to assess the role of BET proteins. Results: Cetuximab‐resistant HNSCC cells expressed elevated PD‐L1 compared to cetuximab‐sensitive controls. Treatment with the BET inhibitor JQ1, the BET PROTAC MZ1, or RNAi‐mediated knockdown of BRD2 decreased PD‐L1 expression. Knockdown of BRD2 also reduced the elevated levels of PD‐L1 seen in a model of acquired cisplatin resistance. Conclusions: PD‐L1 is significantly elevated in HNSCC models of acquired cetuximab and cisplatin resistance where BRD2 is the primary regulator.
- Subjects
CETUXIMAB; IMMUNE checkpoint proteins; SQUAMOUS cell carcinoma; PROGRAMMED death-ligand 1; PROTEIN-tyrosine kinase inhibitors; CISPLATIN
- Publication
Head & Neck, 2021, Vol 43, Issue 11, p3364
- ISSN
1043-3074
- Publication type
Article
- DOI
10.1002/hed.26827